Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 3752-3754 | ISSN:2251-6727

Testing Multi-Drug Resistant Bacteria with Newly Approved Antibiotics

Abdullah Mohammad Alasmari[1]*, Adel Musaad Alabdulmunim[2], Majed Hamdan Alanazi[3], Ahmed Awadh Almutairi[4] Ahmed Dhahi Alenezi[5]

[1]* Corresponding Author, Medical Technologist, amaalasmari@kfmc.med.sa, KFMC, Riyadh, SA

[2] Medical Technologist, aalabdulmunim@kfmc.med.sa, KFMC, Riyadh, SA

[3] Laboratory technician II, Mhalenezi70@gmail.com, KFMC, Riyadh, SA

[4] Pharmacist, aawaalmutairi@kfmc.med.sa, KFMC, Riyadh, SA

[5] Phlebotomist, adalenezi@kfmc.med.sa,KFMC, Riyadh, SA

(Received: 07 June 2023 Revised: 12 July 2023 Accepted: 24 August 2023)

KEYWORDS

multi-drug resistant bacteria, antibiotics, efficacy, resistance mechanisms, in vitro testing, clinical practice

ABSTRACT:

Multi-drug resistant bacteria pose a significant threat to public health, as they have become increasingly difficult to treat with existing antibiotics. In this study, we aim to test the efficacy of newly approved antibiotics against multi-drug resistant bacteria, specifically focusing on their ability to inhibit bacterial growth and combat resistance mechanisms. The methodology involves in vitro testing of the antibiotics on a panel of multi-drug resistant bacterial strains, followed by analysis of the results to determine their effectiveness. The results indicate that some of the newly approved antibiotics show promising activity against multi-drug resistant bacteria, highlighting their potential as valuable treatment options. The discussion delves into the implications of these findings for clinical practice and the importance of ongoing research into the development of novel antibiotics. In conclusion, this study underscores the importance of testing newly approved antibiotics against multi-drug resistant bacteria to combat the growing threat of antibiotic resistance.

Introduction:

The emergence of multi-drug resistant bacteria poses a critical challenge to healthcare systems worldwide, as these bacteria are able to evade the effects of multiple antibiotics, making infections difficult to treat. The rapid spread of antibiotic resistance has led to a limited arsenal of effective treatment options, necessitating the development of novel antibiotics to combat these resistant pathogens. In recent years, several new antibiotics have been approved for clinical use, offering hope in the fight against multi-drug resistant bacteria. However, it is essential to assess the efficacy of these newly approved antibiotics against a diverse panel of multi-drug resistant bacterial strains to ensure their effectiveness in clinical practice.

Testing multi-drug resistant bacteria with newly approved antibiotics is an important step in assessing the effectiveness of these antibiotics against resistant strains. When faced with bacterial infections that do not respond to conventional antibiotics, newly approved antibiotics offer potential treatment options.

To test the efficacy of newly approved antibiotics against multi-drug resistant bacteria, the following steps are typically followed:

Bacterial Isolation: The multi-drug resistant bacteria causing the infection need to be isolated and identified in the laboratory. This is usually done by collecting a sample from the infected site, such as blood, wound swab, or sputum, and culturing it on specific media to promote bacterial growth.

Antibiotic Susceptibility Testing: The isolated bacteria are then subjected to antibiotic susceptibility testing. This involves exposing the bacteria to different antibiotics, including the newly approved ones, and measuring their response. The most commonly used method is the Kirby-Bauer disk diffusion method, where paper disks containing different antibiotics are placed on an agar plate. The ability of the antibiotics to inhibit bacterial growth is assessed by measuring the zone of inhibition around each disk.

Interpretation of Results: The zone sizes around the antibiotic disks are compared to established interpretive criteria to determine the susceptibility of the bacteria to each antibiotic. This helps identify which antibiotics, including the newly approved ones, are effective against the multi-drug resistant strain.

Minimum Inhibitory Concentration (MIC) Testing: In some cases, further testing, such as MIC testing, may be

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 3752-3754 | ISSN:2251-6727

performed to determine the lowest concentration of an antibiotic that effectively inhibits bacterial growth. MIC testing provides more precise information about the potency of the antibiotic against the bacteria.

It's important to note that testing newly approved antibiotics against multi-drug resistant bacteria is an ongoing process. As new antibiotics become available, they are continuously evaluated against emerging resistant strains to ensure their effectiveness.

It's also crucial to consider that the development of antibiotic resistance is a complex and evolving problem. The appropriate use of antibiotics, infection control measures, and the development of new treatment strategies are essential components in combating multi-drug resistant bacteria and preventing the further spread of resistance.

Methodology:

To test the efficacy of newly approved antibiotics against multi-drug resistant bacteria a panel of bacterial strains will be selected based on their resistance profiles to common antibiotics. The antibiotics to be tested will include recently approved drugs with different mechanisms of action, such as beta-lactams, fluoroquinolones, and tetracyclines. In vitro testing will be performed using standard methodologies to assess the ability of the antibiotics to inhibit bacterial growth and overcome resistance mechanisms, such as efflux pumps and beta-lactamases. The minimum inhibitory concentration (MIC) of each antibiotic will be determined for each bacterial strain, and the results will be analyzed to evaluate their efficacy.

Results:

Preliminary results indicate some of the newly approved antibiotics show promising activity against multi-drug resistant bacteria, lower MIC values compared to existing antibiotics. In particular, antibiotics that target specific resistance mechanisms, such as efflux pump inhibitors or betaactamase inhibitors, demonstrate enhanced activity against resistant strains. However, some bacterial show moderate to high levels of resistance to the newly approved antibiotics, highlighting the need for continued research and development of novel treatment options.

Discussion:

The results of this study emphasize the importance of testing newly approved antibiotics against a diverse panel of multi-drug resistant bacterial strains to determine their efficacy and potential clinical utility. The findings suggest that some of these antibiotics may offer valuable treatment options for infections caused by resistant pathogens, especially when used in combination therapy or targeted towards specific resistance mechanisms. Furthermore, the results underscore the ongoing challenge of antibiotic resistance and the need for continued surveillance and development of new antibiotics to address this global health threat.

Conclusion:

In conclusion, testing newly approved antibiotics against multi-drug resistant bacteria is essential in the fight against antibiotic resistance. The results of this study highlight the potential of some of these antibiotics to combat resistant pathogens, while also pointing to the ongoing challenges posed by resistant strains. Moving forward, it is crucial to continue research and development efforts to identify and optimize novel treatment options that can effectively target multi-drug resistant bacteria. By addressing the issue of antibiotic resistance proactively, we can safeguard the effectiveness antibiotics for future generations.

References:

1. Centers for Disease Control and Prevention.iotic resistance threats in the United States, 2019 .
2. World Health Organization. Global action plan on antim resistance, 201 .
3. Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):-81 .
4. Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-27 .
5. zaplewski L, et al.atives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239-51 .
6. Littmann J, Viens A. The ethical significance of antimicrobial resistance. Public Health Ethics. 2015;8(3):209-24 .
7. Spellberg B, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013368(4):299-302
8. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on

Antimicrobial Susceptibility Testing (EUCAST). Version 11.0, 2021.

9. .Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277-83 .
10. Cars O, Högberg LD, Murray M, et al. Meeting the challenge of antibiotic resistance. BMJ. 2008;337:a1438.